Overall, we report the co-expression of different immunosuppressive molecules in FoxP3+Helios+ and FoxP3+Helios− Treg subsets, which might synergistically dampen T-cell activation and function and suppress tumor-specific immune responses in CRC patients. This evidence concerns the gene FOXP3 and neoplasm.